Using an ultra large phage display library, we rapidly identify hits across diverse human antibody formats, with a particular strength in fully human single domain antibodies (sdAbs). We then apply a custom built AI tool to select the best leads from multiple hits, enabling a fast, integrated end to end antibody discovery workflow.

We discover and rigorously characterize high quality fully human antibodies, then use them as modular building blocks to engineer disease and target specific therapeutic modalities. Depending on the biology, we redesign the same antibody into different formats such as bispecifics, T cell engagers, or other antibody derived architectures, and tune key properties like valency, affinity, effector function, and half life. 

We engineer targets into the right “screenable” forms, stable, properly folded, and presented to expose the epitopes we actually want to drug. That antigen design then guides everything downstream, rapid selection of fully human antibodies and, using the same structural and biophysical logic, the design of non antibody biologics such as receptor traps and other engineered binders. In other words, we use antigen engineering as the foundation for building multiple therapeutic protein modalities.